Premium
Efficacy of meclofenamate sodium (Meclomen®) in the treatment of rapidly progressive periodontitis
Author(s) -
Reddy M. S.,
Palcanis K. G.,
Barnett M. L.,
Haigh S.,
Charles C. H.,
Jeffcoat M. K.
Publication year - 1993
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/j.1600-051x.1993.tb00708.x
Subject(s) - medicine , scaling and root planing , placebo , periodontitis , dentistry , radiography , lesion , chronic periodontitis , analysis of variance , nuclear medicine , surgery , pathology , alternative medicine
This 6‐month, double‐blind, controlled clinical trial determined the efficacy of the non‐steroidal anti‐inflammatory drug, meclofenamate sodium (Meclomen®), as an adjunct to scaling and root planing in the treatment of rapidly progressive periodontitis (RPP). 22 subjects (7 male. 15 female) aged 36.5±7.88 years with RPP and disease‐active sites as determined by pretreatment bone scan had standardized radiographs at baseline and 6 months, and clinical measurements at baseline, 3 and 6 months. Following full‐mouth scaling and root planing, subjects were randomly assigned to either a placebo, 50 or 100 mg meclofenamate sodium bid group. Bone change over the 6‐month period as assessed by subtraction radiography was the primary efficacy determinant. Specialized software was used to isolate the lesion from the subtraction image and to measure bone change along the root surface. ANOVA using the subject as the unit of analysis revealed a significant dose response ( P <0.001) with the placebo group having a mean bone loss of 0.42±0.06 mm and the low and high dose groups having mean bone gains of 0.07±0.05 and 0.20±0.07 mm, respectively. These findings indicate that meclofenamate sodium may be a useful adjunct in the treatment of rapidly progressive periodontitis.